



**Pfizer Announces**  
***Inflammation ASPIRE 2019 Rheumatology***  
***International Developed Markets***  
***Competitive Grant Programme***

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an external review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research programme.



## Competitive Grant Programme Eligibility

<b>Geographic Scope</b>	<ul style="list-style-type: none"> <li>Europe, Israel, Turkey, Russia, Australia, New Zealand, Japan and South Korea</li> </ul>
<b>Applicant Eligibility Criteria</b>	<p>To be eligible:</p> <ul style="list-style-type: none"> <li>The principal investigator (PI) and institution must be based in one of the eligible countries noted above.</li> <li>The applicant (PI) must hold an MD, PhD, PharmD or the equivalent</li> <li>Applicant must be affiliated with a host institution</li> <li>Both early career and experienced investigators are encouraged to apply and consideration will be given to all proposals meeting the selection criteria</li> </ul>

## Requirements

<b>Date RFP Issued</b>	<ul style="list-style-type: none"> <li>February 5<sup>th</sup>, 2019</li> </ul>
<b>Clinical Area</b>	<ul style="list-style-type: none"> <li>Pfizer invites investigators to apply for the Inflammation ASPIRE 2019 Research Awards through submission of research proposals with the primary objective to increase understanding of the effect of inhibition of the JAK–STAT pathway on specific clinical effects – looking at either efficacy and/or safety outcomes in rheumatoid arthritis (RA) and spondyloarthritis (SpA), as well as the role of the JAK–STAT pathways in inflammation.</li> </ul>
<b>Area of Interest Focus</b>	<p>The intent of this Request for Proposal (RFP) is to fund clinical research in RA, and psoriatic arthritis (PsA), as well as translational research in PsA, in relation to one or more of the following topics:</p> <ul style="list-style-type: none"> <li>Optimisation of patient treatment with JAK inhibitors (JAKi) in RA             <ul style="list-style-type: none"> <li>Treat-to-target studies in patients on JAKi treatment                 <ul style="list-style-type: none"> <li>Treatment strategies in RA patients in sustained remission whilst on JAKi treatment</li> </ul> </li> <li>Management of JAKi treatment in patients with co-morbidities, with a special interest (but not limited to):                 <ul style="list-style-type: none"> <li>Interstitial lung disease (ILD)</li> </ul> </li> </ul> </li> </ul>

- History of malignancy
  - o Impact of JAKi treatment on very early RA/pre-RA
- Impact of JAK inhibition in SpA in clinical practice
  - o Efficacy of JAKi in monotherapy in PsA
  - o Imaging studies showing the effect of JAKi in structural preservation in PsA and/or axial SpA
  - o Correlation between patient-reported outcomes (PROs) and disease activity in patients treated with JAKi
  - o Effect of JAKi treatment on itch
  - o Management of JAKi treatment in patients with comorbidities, with a special interest (but not limited to):
    - ILD
    - History of malignancy
    - Depression
    - Metabolic syndrome

In addition to the programme-wide areas of interest listed above, there are also special country-specific grants available for 4 target countries (applications from these countries may focus on either the programme-wide areas of interest, the country-specific areas of interest or a combination):

**France:**

- Assessment of therapeutic education vs standard of care in treatment adherence of JAKi
- Efficacy of tofacitinib in enthesitis and axial manifestations
- Characterisation of metabolomic profile of patients in associations with JAKi efficacy

**Germany:**

- Efficacy of JAK inhibition on enthesitis and axial disease/spondylitis in PsA patients
- Experimental studies investigating JAK signaling and inhibition in RA & SpA
- Role of JAK/STAT-signalling in the creatine/phosphocreatine pathway

**The Netherlands:**

- Projects that facilitate multidisciplinary collaboration and/or improve current disease management strategies and value of therapy in RA or PsA
- Projects with a focus on the management of unmet medical needs (e.g., pain, fatigue), treatment monitoring and patient-reported outcomes

**Spain:**

- Role of patients in treat to target strategies with tofacitinib: pain, PRO, fatigue, patients perceptions, etc

- Concomitant treatments in RA patients treated with tofacitinib in remission (CC, FAMEsc)
- RA patients treated with tofacitinib with comorbidities: depression, CV diseases, etc
- RA patients treated with tofacitinib monotherapy/combo and extra-articular manifestations (e.g ILD, ocular involvement, etc)
- Adherence in RA patients treated with tofacitinib
- Effect of tofacitinib in structural preservation in patients with RA
- Treatment of extra-articular manifestations with tofacitinib in patients with PsA
- Management of comorbidities in patients PsA treated with tofacitinib
- Effect of tofacitinib in structural preservation in patients with PsA
- Management of fatty liver in patients with PsA receiving tofacitinib and concomitant therapy

**Italy:**

*There are no additional areas of interest, but additional funding is available for smaller grants (please see “Expected Approximate Monetary Range of Grant Applications” section below for more information)*

**Expected Approximate Monetary Range of Grant Applications**

Programme-wide grants monetary range:

- Individual projects requesting up to €200,000 for RA and €250,000 for SpA will be considered. Overall, €1.15 million have been allocated to the rheumatology programme
- Country-specific special grants - monetary range:
- France – €150,000 is available to fund up to 2 additional grants (with a maximum budget of €120,000 per grant) for French applicants for the French additional areas of interest
- Germany – a total additional budget of €240,000 is available. Individual projects requesting up to €120,000 for clinical research and €60,000 for experimental research will be considered for the German areas of interest
- Netherlands – additional grants of up to €60,000 are available to Netherlands applicants for the Netherlands additional areas of interest
- Italy – two additional grants of up to €70,000 is available for Italian applicants for the programme-wide areas of interest
- Spain - a total budget of €99,000 euros is available to be distributed up to 3 research projects in RA; and a total budget of €135,000 euros is available to be distributed up to 4 research projects in PsA
- The amount of the grant Pfizer will be prepared to fund for any project will depend upon the external review panel's evaluation of the proposal

	and costs involved, and will be stated clearly in the approval notification
<b>Key Dates</b>	<ul style="list-style-type: none"> <li>• RFP release date: February 1<sup>st</sup>, 2019</li> <li>• LOI due date: April 1<sup>st</sup>, 2019</li> </ul> <p>[Please note the deadline is midnight Eastern Time (New York, GMT -5).]</p> <ul style="list-style-type: none"> <li>• Review of LOIs by ERP: Mid-May 2019</li> <li>• Anticipated LOI Notification Date: Mid-May 2019</li> <li>• Full Proposal Deadline: 4 weeks from LOI notification date</li> </ul> <p>*Only accepted LOIs will be invited to submit full proposals. [Please note the deadline is midnight Eastern Time (New York, GMT -5).]</p> <ul style="list-style-type: none"> <li>• Review of Full Proposals by ERP: TBC July 2019</li> <li>• Anticipated Full Proposal Notification Date: August 2019</li> </ul> <p><b>NOTE:</b> Grant funding will be distributed following execution of fully signed Letter of Agreement. Please review the contract language here and before submitting a proposal for consideration, confirm with your institution that you can accept all contract terms. Pfizer considers these terms non-negotiable for grant projects.</p>
<b>How to Apply</b>	<ul style="list-style-type: none"> <li>• Please go to <a href="#">CyberGrants</a> and sign in. First-time users should click “REGISTER NOW”.</li> </ul> <p>Requirements for submission:</p> <ul style="list-style-type: none"> <li>• For programme-wide areas of interest applications, select the following Competitive Grant Program Name: IDM Rheum ASPIRE 2019</li> <li>• For the country-specific special project grants, select the appropriate Competitive Grant Program Name: IDM Rheum ASPIRE France 2019, IDM Rheum ASPIRE Germany 2019, IDM Rheum ASPIRE Netherlands 2019, IDM Rheum ASPIRE Italy 2019 or IDM Rheum ASPIRE Spain 2019. Please remember that for the country-specific special grants, the budget caps differ to the programme-wide grants.</li> <li>• Complete all required sections of the online application. See <a href="#">Appendix A</a> for additional details</li> <li>• If you encounter any technical difficulties with the website, please click the “Need Support?” link at the bottom of the page</li> </ul>
<b>Questions:</b>	<ul style="list-style-type: none"> <li>• If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Jo Harbron (<a href="mailto:jo.harbron@pfizer.com">jo.harbron@pfizer.com</a>), with the subject line “Inflammation ASPIRE 2019 enquiry.”</li> </ul>
<b>Mechanism by which Applicants will be</b>	<ul style="list-style-type: none"> <li>• All applicants will be notified via email by the dates noted above</li> <li>• Applicants may be asked for additional clarification during the review</li> </ul>



Notified:	period
Frequently Asked Questions (FAQs)	<p><b>What are the ASPIRE Research Grants?</b>  ASPIRE are a subset of Pfizer’s competitive research grants. The ASPIRE subset of the competitive grants programme aims to fund research in the disease area of inflammation and immunology across Europe, Israel, Turkey, Russia, Australia, New Zealand, Japan and South Korea. Pfizer is fully funding the ASPIRE Research Grants. Additionally, Pfizer is providing the infrastructure and administrative support required to facilitate the review process, as well as notifying applicants and distributing the research grants. All applications will be formally reviewed by a committee of European medical/scientific experts in the field of the specific appropriate area.  Due to Foreign Corrupt Practices Acts (FCPA) regulations, submissions selected for research grants by the review committee must go through an internal review at Pfizer to ensure provision of the grant is appropriate and relevant information regarding potentially influencing government official status, as well as beneficiaries and controllers’ information, is captured (when applicable).</p> <p><b>Who is eligible to apply for ASPIRE Research Grants?</b>  In 2019, the ASPIRE will focus on European countries, Israel, Turkey, Russia, Australia, New Zealand, Japan and South Korea. ASPIRE applications are possible for any investigator. To be eligible for a research grant, an applicant must hold an MD, PhD, PharmD or the equivalent and must reside in Europe, Israel, Turkey, Russia, Australia, New Zealand, Japan or South Korea.</p> <p><b>Why are there special opportunities for some countries?</b>  In previous years, some countries have had country-specific competitive grant programmes. In 2019, to maximise the available funds to be spent on grants rather than administration, the country specific programmes have been incorporated into the regional programmes leading to additional grant opportunities for some countries</p> <p><b>When will the ASPIRE Research Grants be announced?</b>  The successful grantees will be notified about three months after the deadline. See home page for key dates.</p> <p><b>Is the funding a per-annum or per-study amount?</b>  Each research grant funds the entire research period and is not a sum paid per year.</p> <p><b>Does the funding include Institutional overhead costs and indirect costs?</b>  Yes, the maximum funding for each type of research grant includes indirect costs, and institutional overhead costs. Final budgets of those studies awarded a grant will be reviewed for fair market value before the contracting process begins.</p> <p><b>Are the ASPIRE Research Grants open to researchers working outside one of the countries listed below?</b></p>

No. The ASPIRE Research Grants are open only to researchers in these countries: Europe, Israel, Turkey, Russia, Australia, New Zealand, Japan and South Korea.

**Are there any specific research areas that are excluded from ASPIRE funding?**

The following topics fall outside of the scope of the ASPIRE Programme:

- General education and / or training
- Public health
- Support for research that is already underway
- Support for ongoing clinical programmes that are part of an organization's routine operations

**Can an exception be made for certain applicants regarding the eligibility criteria to the ASPIRE Research Grants?**

The eligibility requirements – academic, scientific, etc. – are designed and maintained by the committee of experts. In keeping with the purpose and intention of the ASPIRE Research Grants, applicants must meet all the criteria in order to be considered for a research grant. Submissions outside these parameters will not be considered.

**Is there a time limit for conducting the funded research?**

Study results are expected three years maximum after the signature of the contract.

**How do I apply for a ASPIRE Research Grant?**

Applications are to be submitted to Pfizer through an online submission website in a 2-step process. Visit [www.cybergrants.com/pfizer/researchgrants](http://www.cybergrants.com/pfizer/researchgrants), follow the process and submit your letter of intent (LOI). These letters of intent are summary proposals, which will be evaluated by a LOI review panel. The LOI review panel will decide which proposals can continue and submit a full proposal through the same website [www.cybergrants.com/pfizer/researchgrants](http://www.cybergrants.com/pfizer/researchgrants).

**I'm having difficulty submitting my application online, who do I contact for assistance?**

Receive assistance by contacting [globalmedicalgrants@pfizer.com](mailto:globalmedicalgrants@pfizer.com)

**What is the deadline for application?**

See information from above.

**When will I hear whether my application has been successful?**

See information from above.

**If my application is successful, when will the funding commence?**

Research grants will commence about 2 months after the notification of the selection, pending receipt of all required documents noted in the application portal.

**Will I receive a copy of the Review Committee's evaluation of my grant**

	<p><b>proposal?</b> The corresponding feedback will be provided in due course to all applicants.</p> <p><b>Can Pfizer drugs be provided?</b> Upon request, and only for clinical research, Pfizer may provide both study drug and/or placebo. In this case drug cost must not be included in the budget template, must be clearly mentioned within the proposal. For all translational research proposals, no drug will be provided, as in this case drug can easily be obtained from third party providers.</p> <p><b>If I receive a research grant, will I become part of the press release in the public domain?</b> If your proposal is awarded a grant, then you will be informed personally before the press release.</p> <p><b>I have a question that is not covered here</b> If you require clarification on an issue not addressed here, please contact the Grant Officer Jo Harbron (<a href="mailto:jo.harbron@pfizer.com">jo.harbron@pfizer.com</a>).</p>
<p><b>Previous ASPIRE winners</b></p>	<p><b>ASPIRE 2018 Awarded proposals in Inflammation Research</b></p> <p><b>Ernest Choy (Cardiff University, UK)</b> Tofacitinib on pain processing in rheumatoid arthritis (ToPPRA)</p> <p><b>James Bluett (University of Manchester, UK)</b> Development and validation of a tofacitinib adherence assay in rheumatoid arthritis - oral adherence</p> <p><b>Costantino Pitzalis (Barts and the London School of Medicine and Dentistry, UK)</b> Phosphoproteomic profiling of tofacitinib response in rheumatoid arthritis (Phospho-Tof-RA)</p> <p><b>Harald Burkhardt (Goethe-University Frankfurt/Main &amp; Fraunhofer Institute for Molecular Biology and Applied Ecology, Germany)</b> Comparison of the capability to taper non-steroidal anti-inflammatory drugs and of treat-to-target guided de-escalation of corticosteroids in newly initiated Tofacitinib or Etanercept therapy to accelerate the clinical relevant decrease of accompanying NSAID and corticosteroid treatment in patients with active Rheumatoid Arthritis and inadequate response to previous csDMARD</p> <p><b>Michael Nurmohamed (Reade, Netherlands)</b> Increased thromboembolic risk during antirheumatic treatment, fact or fiction</p> <p><b>Denis Poddubnyy (Clinic of Gastroenterology, Infectiology and Rheumatology, Campus Benjamin Franklin, Charite - Universitätsmedizin Berlin, Germany)</b> A 24-week, prospective, open-label, proof-of-concept study to evaluate the efficacy of tofacitinib in reducing inflammation detected on MRI in patients with</p>



psoriatic arthritis presenting with axial involvement

**Sander W. Tas (Academic Medical Center/University of Amsterdam, Netherlands)**

The contribution of JAK-STAT signaling to pathological endothelial responses in psoriatic arthritis

**Ursula Fearon (Trinity College Dublin, Ireland)**

To elucidate the effect of tofacitinib on specific polyfunctional T-cells within the PsA-inflamed synovium

**Stefan Schreiber (Medical Department, University Hospital Schleswig Holstein, Campus Kiel & Institute of Clinical Molecular Biology, University Hospital Kiel and Christian-Albrechts-University Kiel, Germany)**

TofaCID\_A systems medicine approach to dissect tofacitinib dependent modulation of signatures of disease and response in chronic inflammatory disease

**Christien van der Woude (Erasmus MC, Netherlands)**

Deep profiling of lipid changes in patients with active ulcerative colitis treated with either tofacitinib or infliximab

**Alessandro Armuzzi (Fondazione Policlinico Universitario A. Gemelli Università Cattolica del Sacro Cuore, Italy)**

Predictive value of colonic mucosal and synovial tissues profiles for response to JAKs inhibitor in patients affected by ulcerative colitis and concomitant peripheral arthritis

**Massimo Fantini (Università Degli Studi di Roma «Tor Vergata», Italy)**

(A)nalysis of immunological (VA)riables in ex vivo (T)ofacitinib-treated human biopsies from (A)ctive ulcerative colitis patients to predict clinical (R)esponse (the AVATAR study)

**Europe ASPIRE 2017 Awarded Proposals in Inflammation Research:**

**Thierry Schaeffer (University Hospital of Bordeaux, France)**

Impact of Tofacitinib on Pain sensitization in Rheumatoid Arthritis patients (TOPRA study)

**Maya H Buch (Leeds Institute of Rheumatic and Musculoskeletal Medicine, United Kingdom)**

Investigating JAK-STAT intracellular signalling in peripheral blood cell subsets using multi-parameter flow cytometry and synovial tissue JAK-STAT to tailor JAK inhibitor therapy in patients with refractory rheumatoid arthritis

**Arthur G Pratt (Newcastle University, United Kingdom)**

Refining a Predictive Biomarker for Effective JAK-STAT Inhibition in Rheumatoid Arthritis

**Silvia D'Alessio (Humanitas Research Hospital, Milano, Italy)**

Unravelling the mechanism of action of Tofacitinib on immune cell trafficking through IBD-associated microvasculature

**Keren M Rabinowitz (Felsenstein Research Medical Center, Petach Tikva, Israel)**

Mechanistic insights into modification of human intestinal immune responses by Janus kinase (JAK) modulation

**Bas Oldenburg (University Medical Centre Utrecht, Netherlands)**

Novel tools to assess mucosal JAK-STAT activity and the effect of therapeutic compounds in patients with Crohn's disease and ulcerative colitis

**Europe ASPIRE 2016 Awarded Proposals in Inflammation Research:**

**Helen L. Wright (Institute of Ageing and Chronic Diseases, University of Liverpool, United Kingdom)**

The effect of JAK inhibition on neutrophil killing, NETosis and metabolism in rheumatoid arthritis

**Marta Rizzi (University Medical Centre Freiburg, Germany)**

Impact of Janus kinase inhibition on human early and late B cell development

**Giovanni Almanzar (University Hospital Wuerzburg, Germany)**

Varicella-zoster-virus-(VZV)-specific cellular immune response of in vitro tofacitinib-treated lymphocytes derived from patients with autoimmune arthritis

**Sergei Nedospasov (Deutsches Rheuma-Forschungszentrum Berlin, Germany)**

Combined blockade of TNF and JAK-STAT pathways in murine models of autoimmune arthritis

**Thomas Karonitsch (Medical University of Vienna, Austria)**

Epigenetic reprogramming of rheumatoid fibroblast-like synoviocytes (RA-FLS) with JAKinibs

**Elisabetta Botti (University of Rome "Tor Vergata", Italy)**

JAK-STAT signaling inhibition on autoantigen driven psoriatic inflammation

**Friederike Berberich-Siebelt (University of Würzburg, Germany)**

A novel Jakinib in the dichotomy of mucosal healing and inflammation -

associated cancer resolution

**Prof. dr. Maikel P. Peppelenbosch (Erasmus MC, Rotterdam)**

The effect of the microbiome on JAK/STAT/SOCS signaling in the intestinal epithelial compartment of IBD patients

**Konrad Aden (Christian-Albrechts-Universität zu Kiel, Germany)**

Dissecting the role of tofacitinib on epithelial stem cell function and intestinal repair

**Europe ASPIRE 2015 Awarded Proposals in Inflammation Research:**

**Thomas Huizinga (Leiden University Medical Center, Netherlands)**

Exploring the disease modifying effects of tofacitinib: Does tofacitinib affect intracellular signalling pathways involved in the regulation of autoantibody production in rheumatoid arthritis?

**Cristina Albanesi (Istituto Dermopatico dell'Immacolata IDI-IRCCS, Italy)**

Immunomodulatory effects of tofacitinib on psoriatic keratinocytes and on its capability to mimic SOCS inhibitory circuits

**Rik Lories (KU Leuven, Belgium)**

Control of cartilage damage by inhibition of JAK-STAT signalling: Identifying signalling networks

**Janneke Nicoline Samsom (Erasmus University Medical Center, Netherlands)**

Tofacitinib to treat inflammatory bowel disease which is driven by defective antigen presenting cell function

**Axel J. Hueber (Friedrich-Alexander University Erlangen-Nuernberg, Germany)**

Dissecting JAK-STAT dependent bone-turnover in autoimmune arthritis

**Europe ASPIRE 2014 Awarded Proposals in Inflammation Research:**

**Dirk Foell (University of Muenster, Germany)**

Regulatory monocytes induced by blocking JAKs in inflammatory diseases

**Antonio Costanzo (Sapienza University of Rome, Italy)**

Effects of JAK3 inhibition on transcriptional landscapes in psoriasis

**Ursula Fearon (St Vincent's University Hospital, Ireland)**

Tofacitinib inhibits synovial invasiveness, bioenergetics and bone resorption in RA

**Eniko Sonkolty (Karolinska University Hospital, Sweden)**

Investigation of the role of microRNAs in the mechanism of action of JAK/STAT

inhibitors in psoriasis

**Markus F. Neurath (University of Erlangen-Nuernberg, Germany)**

Effects of tofacitinib on intestinal epithelial cells and mucosal healing in inflammatory bowel diseases

**Europe ASPIRE 2013 Awarded Proposals in Inflammation Research:**

**Marie-Christophe Boissier (University of Paris 13, France)**

Translational study of tofacitinib-mediated JAK inhibition on neutrophil activation and apoptosis in TNF-alpha-transgenic mice and rheumatoid arthritis

**João Eurico Fonseca (Instituto de Medicina Molecular, Portugal)**

Inhibition of bone and cartilage degradation in rat-induced arthritis treated with tofacitinib

**Thomas Harder (University Hospital Erlangen, Germany)**

Pharmacodynamic risk assessment of immunodeficiency during treatment with JAK3-inhibitors

**Gabriel Herrero-Beaumont (Joint and Bone Research Unit. IIS-Fundación Jiménez Díaz, Spain)**

Effect of tofacitinib in the systemic and trisula inflammatory profile in an experimental model of rheumatoid cachexia

**Jens Thiel (University Hospital Freiburg, Germany)**

Effect of inhibiting JAK-STAT pathways by tofacitinib on B cell differentiation and function

## Appendix A

### Letter of Intent Requirements

The Letter of Intent (LOI) will be accepted via the online application. When answering the LOI questions in the application please keep the following in mind:

<b>Goals and Objectives</b>	<ul style="list-style-type: none"> <li>Provide the main goal of the study and the study population. Provide a detailed definition that is directly linked to the primary objective</li> </ul>
<b>Assessment of Need for the Project</b>	<ul style="list-style-type: none"> <li>This should reflect your study rationale. Provide a brief description of the medical question and the rationale of how this trial addresses the question</li> </ul>
<b>Target Audience</b>	<ul style="list-style-type: none"> <li>Describe the primary audience(s) targeted for this project. For Investigator Sponsored Trials, please specify the age, gender and other demographic information for trial population</li> <li>Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population</li> </ul>
<b>Project Design and Methods</b>	<ul style="list-style-type: none"> <li>Describe concisely the research design and methods for achieving the stated goals. For a clinical interventional study; include inclusion/exclusion criteria, treatment plan and statistical plan</li> </ul>
<b>Innovation</b>	<ul style="list-style-type: none"> <li>Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project</li> </ul>
<b>Evaluation and Outcomes</b>	<ul style="list-style-type: none"> <li>Specify type and frequency of safety, efficacy, and outcome measures. Also indicate the method(s) used to assess measures</li> </ul>
<b>Anticipated Project Timeline</b>	<ul style="list-style-type: none"> <li>Provide an anticipated timeline for your project including project start/end dates</li> </ul>
<b>Additional Information</b>	<ul style="list-style-type: none"> <li>If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here</li> </ul>
<b>Organization Detail</b>	<ul style="list-style-type: none"> <li>This information is used to assess the capability of the organizational resources available to perform the effort proposed. Identify the facilities to be used [laboratory, animal, clinical and “other”]. If appropriate, indicate their capacities, pertinent capabilities, relative proximity and extent of availability to the project</li> </ul>